Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 3, 2005, Pages 193-201

  Li, Ying ^a,c   Fu, Lei ^a,d   Yeo, Hosup ^a   Zhu, Ju Liang ^a   Chou, Chen Kung ^b   Kou, Yueh Hsiung ^b   Yeh, Sheau Farn ^b   Gullen, Elizabeth ^a   Austin, David ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c FUDAN UNIVERSITY   (China)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

DNA inhibition; Gene expression; HBV; Helioxanthin; Hepatitis B

Indexed keywords

ANTIRETROVIRUS AGENT; CORE PROTEIN; HELIOXANTHIN; LAMIVUDINE; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; XANTHINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LYSATE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DNA TRANSCRIPTION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; GENE EXPRESSION; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; WESTERN BLOTTING;

EID: 27244440960     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600305     Document Type: Article

References (36)

1. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S (2003) Resistant to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
2. Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
3. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schroder CH & Hoppe-Seyler F (2001) Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20:6579-6586.
4. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH, Cheng YC, Liotta D & Schinazi R (1992) Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′, 3′- dideoxy- 3′- thiacytidine in the inhibition of hepatitis B virus replication. Journal of Biological Chemistry 267:13938-13942.
5. Chin R & Locarnini S (2003) Treatment of chronic hepatitis B: current challenges and future directions. Reviews in Medical Virology 13:255-272.
6. De Clercq E (1999) Perspectives for the treatment of hepatitis B virus infections. International Journal of Antimicrobial Agents 12:81-95.
7. Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Krämer T, Niewöhner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D & Rubsamen-Waigmann H (2003) Inhibition of hepatitis B virus replication by drug- induced depletion of nucleocapsids. Science 299:893-896.
8. Doong SL, Tsai CH, Schinazi RF, Liotta DC & Cheng YC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′- thiacytidine and related analogues. Proceedings of the National Academy of Sciences, USA 88:8495-8499.
9. Fu L & Cheng YC (2000) Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir- resistant virus. Antimicrobial Agents & Chemotherapy 44:3402-3407.
10. Fu L, Liu SH & Cheng YC (1999) Sensitivity of L-(-)2, 3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochemical Pharmacology 57:1351-1359.
11. Gitlin L & Andino R (2003) Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. Journal of Virology 77:7159-7165.
12. Grove KL, Guo X, Liu SH, Gao Z, Chu CK & Cheng YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Research 55:3008-3011.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, & Brosgart CL; Adefovir Dipivoxil 438 Study Group (2003) Adefovir Dipivoxil for the treatment of hepatitis B e antigen- negative chronic hepatitis B. New England Journal Medicine 348:800-807.
14. Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, Holy A & Schalm SW (1993) Inhibitory effect of 9-(2-phosphonylmethoxyethyl)- adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Research 21:141-153.
15. Karayiannis P (2003) Hepatitis B virus: old, new and future approaches to antiviral treatment. Journal of Antimicrobial Chemotherapy 51:761-785.
16. Kwon JA & Rho HM (2002) Hepatitis B viral core protein activates the hepatitis B viral enhancer II/pregenomic promoter through the nuclear factor kappaB binding site. Biochemistry & Cell Biology 80:445-455.
17. Lan YT, Li J, Liao W & Ou J (1999) Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication. Virology 259:342-348.
18. Lee WM (1997) Hepatitis B virus infection. New England Journal of Medicine 337:1733-1745.
19. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN; on behalf of the Asia Hepatitis Lamivudine Study Group (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rate: results after 3 years therapy. Hepatology 33:1527-1532.
20. Liaw YF (2002) Therapy of chronic hepatitis B: current challenges and opportunities. Journal of Viral Hepatitis 9:393-399.
21. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180.
22. Liaw YF, Leung N, Guan R, Lau G & Merican I (2003) Asian-pacific consensus statement on the management of chronic hepatitis B: an update. Journal of Gastroenterology & Hepatology 18:239-245.
23. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion P L & Kay MA (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology 21:639-644.
24. Morrissey DV, Lee PA, Johnson DA, Overly SL, McSwiggen JA, Beigelman L, Mokler VR, Maloney L, Vargeese C, Bowman K, O'Brien JT, Shaffer CS, Conrad A, Schmid P, Morrey JD, Macejak DG, Pavco PA & Blatt LM (2002) Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. Journal of Viral Hepatitis 9:411-418.
25. Nahvi A, Sudarsan N, Ebert MS, Zou X, Brown KL & Breaker RR (2002) Genetic control by a metabolite binding mRNA. Chemistry & Biology 9:1043-1049.
26. Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA & Locarnini SA (1998) Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)- adenine, an acyclic phosphonate nucleoside analogue. Antimicrobial Agents & Chemotherapy 42:3130-3135.
27. Schaller H & Fischer M (1991) Transcriptional control of hepadnavirus gene expression. Current Topics in Microbiology & Immunology 168:21-39.
28. Seeger C & Mason WS (2000) Hepatitis B virus biology. Microbiology & Molecular Biology Review 64:51-68.
29. Sells MA, Chen ML & Acs G (1987) Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences, USA 84:1005-1009.
30. Shlomai A & Shaul Y (2003) Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37:764-770.
31. Summers J & Mason WS (1982) Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
32. Tiollais P, Pourcel C & Dejean A (1985) The hepatitis B virus. Nature 317:489-495.
33. Weimer T, Salfeld J & Will H (1987) Expression of the hepatitis B virus core gene in vitro and in vivo. Journal of Virology 61:3109-3113.
34. WHO (2000) Hepatitis B. World Health Organization Fact Sheet. (WHO/204). www/who.int/mediacentre/factsheets/fs204/en/
35. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS & Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 119:312-323.
36. Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Huang ES, Austin DJ & Cheng YC (2005) Synthesis and antiviral activity of helioxanthin analogues. Journal of Medicinal Chemistry 48:534-546.